List view / Grid view

OncoC4

 

article

Harnessing the CD24/Siglec-10 pathway: immunotherapy innovation

17 October 2024 | By

Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.